prochlorperazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2274	58-38-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: prochlorperazine mesylate prochlorperazine capazine chlormeprazine chlorperazine meterazin meterazine proazine prochlorpemazine prochlorperazin prochlorpromazine prochlorperazine maleate prochlorperazine edisylate prochlorperazine dimaleate prochlorperzine	A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612) Molecular weight: 373.94 Formula: C20H24ClN3S CLOGP: 4.58 LIPINSKI: 0 HAC: 3 HDO: 0 TPSA: 9.72 ALOGS: -4.53 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

prochlorperazine mesylate
prochlorperazine
capazine
chlormeprazine
chlorperazine
meterazin
meterazine
proazine
prochlorpemazine
prochlorperazin
prochlorpromazine
prochlorperazine maleate
prochlorperazine edisylate
prochlorperazine dimaleate
prochlorperzine

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Molecular weight: 373.94
Formula: C20H24ClN3S
CLOGP: 4.58
LIPINSKI: 0
HAC: 3
HDO: 0
TPSA: 9.72
ALOGS: -4.53
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O
50	mg	P
0.10	g	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	15 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	22 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	9 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 23, 1956	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nausea	300.53	11.37	1426	45718	686028	45952890
Febrile neutropenia	256.41	11.37	391	46753	94236	46544682
Disease progression	235.77	11.37	369	46775	90931	46547987
Drug ineffective	233.58	11.37	206	46938	677632	45961286
Dehydration	197.50	11.37	472	46672	159068	46479850
Vomiting	175.05	11.37	909	46235	451885	46187033
White blood cell count decreased	168.90	11.37	359	46785	111872	46527046
Diarrhoea	147.91	11.37	1017	46127	558585	46080333
Plasma cell myeloma	142.39	11.37	199	46945	44279	46594639
Fatigue	138.91	11.37	1068	46076	607629	46031289
Platelet count decreased	118.31	11.37	291	46853	99733	46539185
Neutropenia	105.31	11.37	351	46793	142853	46496065
Toxicity to various agents	94.42	11.37	48	47096	211718	46427200
Malignant neoplasm progression	92.19	11.37	203	46941	64723	46574195
Constipation	91.49	11.37	383	46761	173714	46465204
Death	89.46	11.37	612	46532	334936	46303982
Rheumatoid arthritis	88.41	11.37	68	47076	240147	46398771
Asthenia	77.95	11.37	559	46585	310516	46328402
Neutrophil count decreased	68.81	11.37	142	47002	43284	46595634
Contraindicated product administered	67.92	11.37	3	47141	79944	46558974
Heart rate abnormal	64.27	11.37	41	47103	3346	46635572
Decreased appetite	64.24	11.37	374	46770	193462	46445456
Blood magnesium decreased	62.79	11.37	66	47078	10926	46627992
Full blood count decreased	60.33	11.37	92	47052	22119	46616799
Akathisia	58.37	11.37	54	47090	7660	46631258
Neoplasm progression	58.14	11.37	100	47044	26583	46612335
Completed suicide	57.98	11.37	38	47106	145882	46493036
Neuropathy peripheral	56.58	11.37	211	46933	90682	46548236
Pleural effusion	56.23	11.37	198	46946	82754	46556164
Carbohydrate antigen 125 increased	55.48	11.37	33	47111	2377	46636541
Hospice care	54.10	11.37	44	47100	5251	46633667
Lymphadenitis	53.11	11.37	33	47111	2572	46636346
Thrombosis	51.88	11.37	149	46995	55920	46582998
Therapeutic product effect incomplete	50.43	11.37	9	47135	78144	46560774
Clostridium difficile infection	49.43	11.37	90	47054	25013	46613905
Joint swelling	49.32	11.37	57	47087	166016	46472902
Small intestinal obstruction	48.24	11.37	70	47074	16102	46622816
Injection site erythema	47.10	11.37	9	47135	74418	46564500
Therapeutic product effect decreased	46.30	11.37	13	47131	82588	46556330
Arthropathy	46.25	11.37	14	47130	84686	46554232
Abdominal pain	44.64	11.37	390	46754	229641	46409277
Gangrene	43.77	11.37	37	47107	4658	46634260
Systemic lupus erythematosus	43.17	11.37	7	47137	65173	46573745
Cytokine release syndrome	42.20	11.37	41	47103	6182	46632736
Coma	41.62	11.37	5	47139	58344	46580574
Injection site pain	41.09	11.37	29	47115	107123	46531795
Condition aggravated	39.34	11.37	122	47022	244930	46393988
Pancytopenia	39.16	11.37	180	46964	84878	46554040
Arterial occlusive disease	39.03	11.37	35	47109	4769	46634149
Colitis	38.24	11.37	103	47041	37244	46601674
Thrombocytopenia	37.90	11.37	238	46906	126343	46512575
Psoriasis	37.79	11.37	16	47128	78588	46560330
Treatment failure	37.29	11.37	24	47120	93063	46545855
Intentional overdose	34.97	11.37	11	47133	64933	46573985
Palmar-plantar erythrodysaesthesia syndrome	34.91	11.37	69	47075	20382	46618536
Pneumonitis	32.82	11.37	82	47062	28338	46610580
Blood creatine increased	32.55	11.37	31	47113	4559	46634359
Rectal cancer metastatic	30.35	11.37	11	47133	249	46638669
Injection site reaction	29.82	11.37	6	47138	47843	46591075
Failure to thrive	29.45	11.37	35	47109	6629	46632289
Pneumonia	29.32	11.37	538	46606	375782	46263136
Drug hypersensitivity	29.16	11.37	375	46769	243450	46395468
Muscle twitching	28.12	11.37	52	47092	14620	46624298
General physical health deterioration	28.05	11.37	46	47098	115723	46523195
Stomatitis	27.44	11.37	139	47005	68158	46570760
Drug interaction	27.29	11.37	109	47035	202985	46435933
Red blood cell count decreased	26.67	11.37	83	47061	32540	46606378
Psoriatic arthropathy	26.23	11.37	3	47141	36376	46602542
Taste disorder	26.19	11.37	31	47113	5847	46633071
Injection site swelling	25.25	11.37	5	47139	40322	46598596
Overdose	25.20	11.37	40	47104	101939	46536979
Mucosal inflammation	24.66	11.37	91	47053	38885	46600033
Hypokalaemia	24.18	11.37	162	46982	87862	46551056
Anaemia	24.01	11.37	377	46767	255402	46383516
Gastric disorder	23.76	11.37	70	47074	26635	46612283
Suicide attempt	23.71	11.37	13	47131	55023	46583895
Hypophagia	23.44	11.37	74	47070	29232	46609686
Cholestasis of pregnancy	22.31	11.37	14	47130	1110	46637808
Weight decreased	22.20	11.37	317	46827	210532	46428386
Dysgeusia	21.92	11.37	90	47054	40401	46598517
Lymphadenopathy	21.87	11.37	79	47065	33409	46605509
Tumour marker increased	21.55	11.37	22	47122	3519	46635399
Pyrexia	21.28	11.37	481	46663	348321	46290597
Sepsis	21.07	11.37	220	46924	135794	46503124
Blood potassium decreased	20.92	11.37	85	47059	37978	46600940
Abortion spontaneous	20.79	11.37	9	47135	43637	46595281
Skull fracture	20.05	11.37	12	47132	874	46638044
Off label use	19.99	11.37	267	46877	379574	46259344
Haemoglobin decreased	19.70	11.37	208	46936	128741	46510177
Coronary artery disease	19.50	11.37	5	47139	33747	46605171
Mobility decreased	18.84	11.37	20	47124	60574	46578344
Maternal exposure during pregnancy	18.68	11.37	48	47096	102501	46536417
Pain	18.20	11.37	356	46788	476592	46162326
Hyponatraemia	18.17	11.37	169	46975	101163	46537755
Asthma	18.14	11.37	41	47103	91501	46547417
Autoimmune nephritis	17.85	11.37	8	47136	318	46638600
Injection site pruritus	17.69	11.37	9	47135	39734	46599184
Dry skin	17.55	11.37	85	47059	40931	46597987
C-reactive protein increased	17.49	11.37	20	47124	58570	46580348
Oral pain	17.49	11.37	60	47084	24737	46614181
Acquired cystic kidney disease	17.47	11.37	5	47139	51	46638867
Cardiac failure	17.35	11.37	34	47110	79914	46559004
Hypermagnesaemia	17.10	11.37	11	47133	911	46638007
Back pain	16.90	11.37	302	46842	209737	46429181
Skin exfoliation	16.88	11.37	72	47072	32866	46606052
Morbid thoughts	16.75	11.37	9	47135	533	46638385
Drug abuse	16.50	11.37	24	47120	63384	46575534
Injection site bruising	15.96	11.37	8	47136	35628	46603290
Drug reaction with eosinophilia and systemic symptoms	15.91	11.37	5	47139	29543	46609375
Exposure during pregnancy	15.87	11.37	56	47088	108156	46530762
Laboratory test abnormal	15.86	11.37	55	47089	22792	46616126
Hypoxia	15.82	11.37	98	47046	51740	46587178
Neutropenic sepsis	15.77	11.37	37	47107	12287	46626631
Glossodynia	15.73	11.37	13	47131	44360	46594558
Pancreatic carcinoma recurrent	15.02	11.37	5	47139	87	46638831
Clostridium difficile colitis	14.97	11.37	47	47097	18506	46620412
Mental status changes	14.93	11.37	77	47067	38011	46600907
Musculoskeletal stiffness	14.85	11.37	50	47094	97943	46540975
Knee arthroplasty	14.68	11.37	3	47141	23662	46615256
Deep vein thrombosis	14.27	11.37	133	47011	79640	46559278
Lymph node pain	14.19	11.37	11	47133	1225	46637693
Lower respiratory tract infection	14.18	11.37	21	47123	55068	46583850
Hypomagnesaemia	14.17	11.37	52	47092	22158	46616760
Multiple sclerosis relapse	14.14	11.37	13	47131	42112	46596806
Dyssomnia	14.14	11.37	4	47140	39	46638879
Red blood cell sedimentation rate increased	13.99	11.37	3	47141	22886	46616032
Drug intolerance	13.97	11.37	89	47055	146960	46491958
Ovarian cancer recurrent	13.84	11.37	10	47134	1001	46637917
Fibromyalgia	13.79	11.37	10	47134	36453	46602465
Multiple sclerosis	13.70	11.37	4	47140	24787	46614131
Blood pressure fluctuation	13.39	11.37	7	47137	30441	46608477
Myocardial infarction	13.30	11.37	52	47092	97476	46541442
Product quality issue	13.20	11.37	10	47134	35638	46603280
Intentional self-injury	13.17	11.37	4	47140	24162	46614756
Red cell distribution width increased	13.16	11.37	26	47118	7678	46631240
Pericarditis	12.97	11.37	4	47140	23923	46614995
Osteonecrosis	12.76	11.37	5	47139	25739	46613179
Acute myeloid leukaemia	12.76	11.37	40	47104	15738	46623180
Plasmacytoma	12.61	11.37	14	47130	2463	46636455
Therapeutic response decreased	12.58	11.37	15	47129	43130	46595788
Infusion related reaction	12.54	11.37	56	47088	101152	46537766
Weight increased	12.52	11.37	106	47038	164367	46474551
Accidental exposure to product	12.41	11.37	3	47141	21078	46617840
Adverse drug reaction	12.39	11.37	82	47062	44280	46594638
Breast cancer metastatic	12.30	11.37	36	47108	13642	46625276
Pregnancy	12.30	11.37	6	47138	27131	46611787
Gastrointestinal injury	12.23	11.37	7	47137	469	46638449
No adverse event	12.17	11.37	10	47134	34221	46604697
Intentional product misuse	12.10	11.37	18	47126	47110	46591808
Hepatitis	11.97	11.37	9	47135	32206	46606712
Arthralgia	11.88	11.37	279	46865	364324	46274594
Loss of personal independence in daily activities	11.83	11.37	25	47119	57158	46581760
Breast cellulitis	11.69	11.37	7	47137	510	46638408
Heart rate decreased	11.61	11.37	9	47135	31714	46607204
Hepatic enzyme increased	11.54	11.37	43	47101	81744	46557174
Non-small cell lung cancer	11.47	11.37	15	47129	3129	46635789
Lymphatic disorder	11.39	11.37	6	47138	341	46638577

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	230.07	11.89	406	31056	106287	29814729
Nausea	218.57	11.89	745	30717	296212	29624804
Fatigue	162.32	11.89	715	30747	319958	29601058
Disease progression	135.95	11.89	275	31187	79599	29841417
Dehydration	116.03	11.89	338	31124	123201	29797815
Plasma cell myeloma	109.25	11.89	199	31263	53263	29867753
Malignant neoplasm progression	102.33	11.89	231	31231	72056	29848960
Vomiting	93.02	11.89	466	30996	219352	29701664
Pneumonia	87.69	11.89	625	30837	333681	29587335
Diarrhoea	78.14	11.89	608	30854	333495	29587521
Death	75.88	11.89	636	30826	356647	29564369
Decreased appetite	75.11	11.89	334	31128	149576	29771440
Drug abuse	67.08	11.89	5	31457	82067	29838949
Toxicity to various agents	65.57	11.89	54	31408	177129	29743887
Drug interaction	62.07	11.89	71	31391	199497	29721519
Full blood count decreased	52.08	11.89	73	31389	15644	29905372
Completed suicide	49.92	11.89	21	31441	99471	29821545
White blood cell count decreased	49.73	11.89	197	31265	83750	29837266
Constipation	48.72	11.89	241	31221	112665	29808351
Neuropathy peripheral	48.04	11.89	173	31289	70302	29850714
Platelet count decreased	46.83	11.89	228	31234	105901	29815115
Drug ineffective	42.94	11.89	198	31264	340189	29580827
Condition aggravated	40.73	11.89	51	31411	137815	29783201
Neutropenia	38.63	11.89	249	31213	128291	29792725
Overdose	37.43	11.89	21	31441	84316	29836700
Small intestinal obstruction	36.01	11.89	57	31405	13602	29907414
Neutrophil count decreased	35.81	11.89	112	31350	42342	29878674
Cytokine release syndrome	32.70	11.89	46	31416	9887	29911129
Failure to thrive	32.18	11.89	41	31421	8013	29913003
Back pain	30.95	11.89	199	31263	102397	29818619
Neoplasm progression	29.33	11.89	61	31401	17962	29903054
Psoriasis	28.73	11.89	5	31457	42501	29878515
Asthenia	28.45	11.89	356	31106	220934	29700082
Intentional overdose	27.77	11.89	5	31457	41476	29879540
Cardiac failure	25.52	11.89	30	31432	83388	29837628
Deep vein thrombosis	25.24	11.89	128	31334	60373	29860643
Coma	24.76	11.89	6	31456	40443	29880573
Sepsis	24.45	11.89	248	31214	146147	29774869
Rheumatoid arthritis	23.54	11.89	7	31455	41190	29879826
Suicide attempt	23.35	11.89	5	31457	36692	29884324
Hospice care	23.29	11.89	26	31436	4426	29916590
Pulmonary embolism	23.21	11.89	151	31311	77984	29843032
Rash	23.07	11.89	305	31157	191584	29729432
Bradycardia	22.94	11.89	21	31441	65505	29855511
Muscle spasms	22.86	11.89	131	31331	64707	29856309
Therapeutic product effect incomplete	22.82	11.89	4	31458	33830	29887186
Rhabdomyolysis	22.70	11.89	20	31442	63560	29857456
Ageusia	21.74	11.89	36	31426	8917	29912099
Intentional product misuse	21.50	11.89	5	31457	34662	29886354
Hyponatraemia	21.27	11.89	132	31330	67070	29853946
Coronary artery disease	21.17	11.89	13	31449	49699	29871317
Thrombosis	20.99	11.89	94	31368	42137	29878879
Product use in unapproved indication	20.97	11.89	28	31434	73665	29847351
Laboratory test abnormal	20.59	11.89	52	31410	17390	29903626
Wrong technique in product usage process	20.33	11.89	4	31458	31151	29889865
Oral pain	20.27	11.89	36	31426	9433	29911583
Spinal cord compression	20.20	11.89	22	31440	3644	29917372
Dysgeusia	19.60	11.89	64	31398	24737	29896279
Weight decreased	18.58	11.89	241	31221	150680	29770336
Adverse drug reaction	18.54	11.89	60	31402	23085	29897931
Plasma cell myeloma recurrent	17.96	11.89	20	31442	3394	29917622
C-reactive protein increased	17.65	11.89	12	31450	43461	29877555
Injection site pain	17.59	11.89	5	31457	30305	29890711
Mixed dementia	17.26	11.89	7	31455	208	29920808
Pleural effusion	16.71	11.89	134	31328	73932	29847084
Mental status changes	16.56	11.89	80	31382	36999	29884017
General physical health deterioration	16.49	11.89	52	31410	99892	29821124
Diaphragmatic rupture	16.29	11.89	4	31458	20	29920996
Drug reaction with eosinophilia and systemic symptoms	15.99	11.89	5	31457	28483	29892533
Pneumonitis	15.88	11.89	64	31398	27390	29893626
Hiccups	15.43	11.89	32	31430	9402	29911614
Myocardial infarction	15.21	11.89	74	31388	125551	29795465
Treatment failure	14.86	11.89	9	31453	34670	29886346
Limb reduction defect	14.71	11.89	6	31456	181	29920835
Clostridium difficile infection	14.57	11.89	43	31419	15740	29905276
Inferior vena caval occlusion	14.37	11.89	4	31458	35	29920981
Wrist deformity	14.15	11.89	7	31455	335	29920681
Oral candidiasis	14.11	11.89	34	31428	11037	29909979
Cholangiocarcinoma	13.78	11.89	10	31452	969	29920047
Pancytopenia	13.65	11.89	143	31319	84909	29836107
Respiratory arrest	13.39	11.89	7	31455	29251	29891765
Fluid imbalance	13.31	11.89	7	31455	381	29920635
Electrocardiogram QT prolonged	13.12	11.89	11	31451	35824	29885192
Anaemia	13.08	11.89	298	31164	207694	29713322
Hypophagia	12.99	11.89	52	31410	22184	29898832
Cholestasis	12.93	11.89	5	31457	24945	29896071
Meconium abnormal	12.76	11.89	3	31459	12	29921004
Foetal exposure during pregnancy	12.68	11.89	12	31450	36859	29884157
Immune effector cell-associated neurotoxicity syndrome	12.63	11.89	9	31453	847	29920169
Tooth disorder	12.62	11.89	29	31433	9132	29911884
Seizure	12.51	11.89	57	31405	98418	29822598
Therapeutic response decreased	12.42	11.89	5	31457	24344	29896672
Toothache	12.32	11.89	22	31440	5789	29915227
Muscular weakness	12.17	11.89	111	31351	63534	29857482

Pharmacologic Action:

Source	Code	Description
ATC	N05AB04	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperazine structure
FDA CS	M0016525	Phenothiazines
FDA EPC	N0000175746	Phenothiazine
MeSH PA	D000932	Antiemetics
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:37890	alpha-adrenoceptor antagonists
CHEBI has role	CHEBI:48561	dopamine blocker
CHEBI has role	CHEBI:48873	anticholinergika
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:65190	typical antipsychotic drug
CHEBI has role	CHEBI:76779	prolyl oligopeptidase (ec 3.4.21.26) inhibitor
CHEBI has role	CHEBI:131787	d2 receptor antagonist

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Nausea and vomiting	indication	16932000
Schizophrenia	indication	58214004	DOID:5419
Nonpsychotic Anxiety	indication
Prolonged-Severe Nausea and Vomiting	indication
Migraine	off-label use	37796009	DOID:6364
Chemotherapy-induced nausea and vomiting	off-label use	236084000
Brain damage	contraindication	2470005
Tachyarrhythmia	contraindication	6285003
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Severe chronic ulcerative colitis	contraindication	14311001
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Toxic megacolon	contraindication	28536002	DOID:1770
Orthostatic hypotension	contraindication	28651003
Atony of colon	contraindication	29479008
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Conduction disorder of the heart	contraindication	44808001
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Ulcerative colitis	contraindication	64766004	DOID:8577
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Extrapyramidal disease	contraindication	76349003
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Hyperglycemia	contraindication	80394007	DOID:4195
Hiatal hernia	contraindication	84089009	DOID:12642
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Gastrointestinal obstruction	contraindication	126765001
Acute disease of cardiovascular system	contraindication	128487001
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Angina pectoris	contraindication	194828000
Myocardial dysfunction	contraindication	233928007
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Drowsy	contraindication	271782001
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Visual impairment	contraindication	397540003
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.74	Basic
pKa2	4.74	Basic
pKa3	2.21	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	ANTAGONIST	Ki	8.61	WOMBAT-PK	IUPHAR
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.76	WOMBAT-PK	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	7.20	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.64	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	5.82	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.21	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.40	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.19	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.91	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	8.32	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.61	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.96	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.49	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.72	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.80	DRUG MATRIX
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.92	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.86	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	6.52	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.89	DRUG MATRIX
Cytochrome P450 1A2	Enzyme	P05177	CP1A2_HUMAN		IC50	5.70	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.25	DRUG MATRIX
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	7.17	WOMBAT-PK
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	7.72	WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7.62	WOMBAT-PK
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.91	WOMBAT-PK
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.82	WOMBAT-PK
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.30	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.23	PDSP
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	7.11	DRUG MATRIX
5-hydroxytryptamine receptor 4	GPCR		5HT4R_CAVPO		Ki	6.71	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.31	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	5.92	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.38	DRUG MATRIX
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	5.77	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	6.02	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	7.49	CHEMBL

External reference:

ID	Source
4018001	VUID
N0000146346	NUI
D00479	KEGG_DRUG
1257-78-9	SECONDARY_CAS_RN
4017999	VANDF
4018000	VANDF
4018001	VANDF
C4256066	UMLSCUI
CHEBI:8435	CHEBI
P77	PDB_CHEM_ID
DB00433	DRUGBANK_ID
CHEMBL728	ChEMBL_ID
CHEMBL1201154	ChEMBL_ID
CHEMBL1200587	ChEMBL_ID
CHEMBL1314751	ChEMBL_ID
D011346	MESH_DESCRIPTOR_UI
4917	PUBCHEM_CID
7279	IUPHAR_LIGAND_ID
699	INN_ID
YHP6YLT61T	UNII
235739	RXNORM
2073	MMSL
5361	MMSL
5362	MMSL
5363	MMSL
6416	MMSL
6417	MMSL
d00355	MMSL
001478	NDDF
001479	NDDF
001480	NDDF
003466	NDDF
22827004	SNOMEDCT_US
372853006	SNOMEDCT_US
3823007	SNOMEDCT_US
395843006	SNOMEDCT_US
79129001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5105	TABLET, FILM COATED	5 mg	ORAL	ANDA	14 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5110	TABLET, FILM COATED	10 mg	ORAL	ANDA	14 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	0440-8190	TABLET	5 mg	ORAL	ANDA	12 sections
Compro	HUMAN PRESCRIPTION DRUG LABEL	1	0574-7226	SUPPOSITORY	25 mg	RECTAL	ANDA	19 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-2519	TABLET, FILM COATED	5 mg	ORAL	ANDA	12 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-2520	TABLET, FILM COATED	10 mg	ORAL	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6135	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
Prochlorperazine	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0135	SUPPOSITORY	25 mg	RECTAL	ANDA	13 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5020	TABLET, FILM COATED	5 mg	ORAL	ANDA	18 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5021	TABLET, FILM COATED	10 mg	ORAL	ANDA	18 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-281	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-511	TABLET	5 mg	ORAL	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	14789-700	INJECTION	5 mg	INTRAMUSCULAR	ANDA	17 sections
PROCHLORPERAZINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-327	TABLET	10 mg	ORAL	ANDA	10 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-571	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-572	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-294	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
PROCHLORPERAZINE EDISYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-497	INJECTION	5 mg	INTRAMUSCULAR	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-523	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-141	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-550	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	42291-728	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	42291-729	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	42708-103	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	43063-353	TABLET, FILM COATED	5 mg	ORAL	ANDA	14 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-742	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE EDISYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	43066-090	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0109	TABLET, FILM COATED	5 mg	ORAL	ANDA	15 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0110	TABLET, FILM COATED	5 mg	ORAL	ANDA	15 sections
Prochlorperazine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0636	SUPPOSITORY	25 mg	RECTAL	ANDA	13 sections